Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves' disease.

Erbil Y, Giriş M, Salmaslioglu A, Ozluk Y, Barbaros U, Yanik BT, Kapran Y, Abbasoglu SD, Ozarmagan S.

Surgery. 2008 Feb;143(2):216-25. doi: 10.1016/j.surg.2007.07.036. Epub 2007 Dec 21.

PMID:
18242338
2.

Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease.

Erbil Y, Ozluk Y, Giriş M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarmağan S, Tezelman S.

J Clin Endocrinol Metab. 2007 Jun;92(6):2182-9. Epub 2007 Mar 27.

PMID:
17389702
3.

Estimation of antithyroid drug dose in Graves' disease: value of quantification of thyroid blood flow with color duplex sonography.

Saleh A, Fürst G, Feldkamp J, Godehardt E, Grust A, Mödder U.

Ultrasound Med Biol. 2001 Aug;27(8):1137-41.

PMID:
11527601
4.

The value of color flow Doppler ultrasonography of the superior thyroid artery in the surgical management of Graves disease.

Huang SM, Chow NH, Lee HL, Wu TJ.

Arch Surg. 2003 Feb;138(2):146-51; discussion 151.

PMID:
12578408
5.

Prediction of relapse after antithyroid drug therapy of Graves' disease: value of color Doppler sonography.

Saleh A, Cohnen M, Fürst G, Mödder U, Feldkamp J.

Exp Clin Endocrinol Diabetes. 2004 Oct;112(9):510-3.

PMID:
15505758
6.

Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.

Nagasaki T, Inaba M, Kumeda Y, Fujiwara-Ueda M, Hiura Y, Nishizawa Y.

Biomed Pharmacother. 2007 Sep;61(8):472-6. Epub 2007 Mar 7.

PMID:
17420111
7.

Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.

Baldini M, Castagnone D, Rivolta R, Meroni L, Pappalettera M, Cantalamessa L.

Thyroid. 1997 Dec;7(6):823-8.

PMID:
9459623
8.

Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.

Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Suzuki M, Yoshihara A, Ito K, Ito K.

Thyroid. 2014 Feb;24(2):200-7. doi: 10.1089/thy.2012.0612. Epub 2013 Nov 13.

PMID:
23926918
9.

Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.

Kallner G, Vitols S, Ljunggren JG.

J Intern Med. 1996 Jun;239(6):525-9.

PMID:
8656146
10.
11.

[Evaluation of the medical treatment of Graves' disease (GD)].

Peixoto MC, Coeli CM, Vaisman M.

Arq Bras Endocrinol Metabol. 2005 Jun;49(3):410-9. Epub 2006 Mar 16. Portuguese.

12.

Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease.

Huang SM, Liao WT, Lin CF, Sun HS, Chow NH.

World J Surg. 2016 Mar;40(3):505-9. doi: 10.1007/s00268-015-3298-8.

PMID:
26546192
13.

Effect of preoperative iodine in patients with Graves' disease controlled with antithyroid drugs and thyroxine.

Kaur S, Parr JH, Ramsay ID, Hennebry TM, Jarvis KJ, Lester E.

Ann R Coll Surg Engl. 1988 May;70(3):123-7.

14.

Comparison of antithyroid drugs efficacy on P wave changes in patients with Graves' disease.

Berker D, Işik S, Canbay A, Aydin Y, Tütüncü Y, Delibaşi T, Güler S.

Anadolu Kardiyol Derg. 2009 Aug;9(4):298-303.

15.
16.

Treatment outcome of Graves' disease in Thai children.

Somnuke PH, Pusuwan P, Likitmaskul S, Santiprabhob J, Sawathiparnich P.

J Med Assoc Thai. 2007 Sep;90(9):1815-20.

PMID:
17957924
17.

Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism.

Tomaski SM, Mahoney EM, Burgess LP, Raines KB, Bornemann M.

Laryngoscope. 1997 Aug;107(8):1066-70.

PMID:
9261010
19.

Utility of colour Doppler sonography in patients with Graves' disease.

Kumar KV, Vamsikrishna P, Verma A, Muthukrishnan J, Rayudu BR, Modi KD.

West Indian Med J. 2009 Dec;58(6):566-70.

PMID:
20583684
20.

Supplemental Content

Support Center